Israeli drug company SciVac has developed a third generation vaccine for Hepatitis B that it believes will halt the global growth of the disease.
Nearly 600,000 people die annually from Hepatitis B, according to the World Health Organization. They also say as many as 400 million people are carriers for the disease.
SciVec CEO Michal Ben Attar says they are optimistic the new vaccine will change those numbers.
"No more people need to die from this disease," said Ben Attar. "We can eradicate this disease like vaccines did to small pox, diphtheria, tetanus."
The current second generation, yeast-based vaccine has been around for more than 20 years. SciVac however, says that ten percent of newborn babies and 25 percent of adults over 40 do not respond to it.
Ben Attar says the new vaccine is 100 percent effective against Hepatitis B.
SciVec has applied to the U.S. FDA for distribution of the vaccine, and if they receive that approval, they plan to seek similar approval in Europe.
Persons with disabilities who need assistance with issues relating to the content of this station's public inspection file should contact Administrative Assistant Sandy Youngblut at 319-291-1259. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, at 888-835-5322 (TTY) or at email@example.com.